AnaBios Boosts Discovery of Safer, More Effective Medicines With License From the University of Louisville
February 14, 2023 09:00 ET
|
AnaBios
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- AnaBios, a preclinical contract research organization that provides ex vivo human platforms to de-risk new drugs, today announced a technology transfer...
AnaBios Announces Inaugural Translational Research Conference to Be Held in San Diego
November 08, 2022 09:00 ET
|
AnaBios
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AnaBios today announced the inaugural Translational Research Conference to be held Feb. 27-28, 2023, in San Diego, California. The conference will gather...
AnaBios Further Expands Business Development Team With Hiring of Dr. Blake Anson
June 14, 2022 09:00 ET
|
AnaBios
SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- AnaBios is pleased to announce the hire of Blake Anson, Ph.D., as Vice President of Business Development. In this new role, Dr. Anson will contribute to...
AnaBios Closes Financing With Ampersand Capital Partners
June 07, 2022 09:00 ET
|
AnaBios
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- AnaBios Corporation, a leading preclinical contract research organization (CRO) that focuses on translational research with unique capabilities to...
AnaBios Introduces High-Quality Human Primary Liver Cells for Preclinical Drug Discovery
March 24, 2022 08:00 ET
|
AnaBios
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Today, AnaBios announced it will start providing high-quality human primary liver cells to pharmaceutical, biotech and academic laboratories to further...
NIH/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain States
September 30, 2021 11:00 ET
|
AnaBios
SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), has awarded AnaBios a $1,734,409...